Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jan;41(1):148–155. doi: 10.1128/aac.41.1.148

MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents.

S K Spangler 1, M R Jacobs 1, P C Appelbaum 1
PMCID: PMC163676  PMID: 8980771

Abstract

Agar dilution MIC methodology was used to test the activities of GV 118819X (sanfetrinem), ampicillin, amoxicillin, amoxicillin-clavulanate, cefpodoxime, loracarbef, levofloxacin, clarithromycin, ceftriaxone, imipenem, and vancomycin against 53 penicillin-susceptible, 84 penicillin-intermediate and 74 penicillin-resistant pneumococci isolated in the United States. GV 118819X was the most active oral beta-lactam, with MIC at which 50% of the isolates were inhibited (MIC50)/MIC90 values of 0.008/0.03, 0.06/0.5, and 0.5/1.0 micrograms/ml against penicillin-susceptible, -intermediate, and -resistant stains, respectively. Amoxicillin and amoxicillin in the presence of clavulanate (2:1) were the second most-active oral beta-lactams, followed by ampicillin and cefpodoxime; loracarbef was not active against penicillin-intermediate and -resistant strains. Clarithromycin was most active against penicillin-susceptible strains but was less active against intermediate and resistant stains. All pneumococcal stains were inhibited by ceftriaxone and imipenem at MICs of < or = 4.0 and < or = 1.0 micrograms/ml, respectively. The activities of levofloxacin and vancomycin were unaffected by penicillin susceptibility. Time-kill studies of three penicillin-susceptible, three penicillin-intermediate, and three penicillin-resistant pneumococci showed that all compounds, at the broth microdilution MIC, yielded 99.9% killing of all strains after 24 h. Kinetic patterns of all oral beta-lactams, ceftriaxone, and vancomycin were similar relative to the MIC, with 90% killing of all strains first observed after 12 h. However, killing by amoxicillin-clavulanate, imipenem, and levofloxacin was slightly faster and that by clarithromycin was slower than that by the above-described drugs. At 2 x the MIC, more strains were killed earlier than was the case at the MIC, but the pattern seen at the MIC prevailed. When MICs and kill kinetics were combined, sanfetrinem was the most active oral antipneumococcal agent in this study.

Full Text

The Full Text of this article is available as a PDF (5.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992 Jul;15(1):77–83. doi: 10.1093/clinids/15.1.77. [DOI] [PubMed] [Google Scholar]
  2. Barry A. L., Pfaller M. A., Fuchs P. C., Packer R. R. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother. 1994 Oct;38(10):2419–2425. doi: 10.1128/aac.38.10.2419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Block S. L., Harrison C. J., Hedrick J. A., Tyler R. D., Smith R. A., Keegan E., Chartrand S. A. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Pediatr Infect Dis J. 1995 Sep;14(9):751–759. doi: 10.1097/00006454-199509000-00005. [DOI] [PubMed] [Google Scholar]
  4. Breiman R. F., Butler J. C., Tenover F. C., Elliott J. A., Facklam R. R. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994 Jun 15;271(23):1831–1835. [PubMed] [Google Scholar]
  5. Di Modugno E., Erbetti I., Ferrari L., Galassi G., Hammond S. M., Xerri L. In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria. Antimicrob Agents Chemother. 1994 Oct;38(10):2362–2368. doi: 10.1128/aac.38.10.2362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Friedland I. R., McCracken G. H., Jr Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med. 1994 Aug 11;331(6):377–382. doi: 10.1056/NEJM199408113310607. [DOI] [PubMed] [Google Scholar]
  7. Jacobs M. R. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae. Clin Infect Dis. 1992 Jul;15(1):119–127. doi: 10.1093/clinids/15.1.119. [DOI] [PubMed] [Google Scholar]
  8. Liñares J., Alonso T., Pérez J. L., Ayats J., Domínguez M. A., Pallarés R., Martín R. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics. J Antimicrob Chemother. 1992 Sep;30(3):279–288. doi: 10.1093/jac/30.3.279. [DOI] [PubMed] [Google Scholar]
  9. Liñares J., Pallares R., Alonso T., Perez J. L., Ayats J., Gudiol F., Viladrich P. F., Martin R. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis. 1992 Jul;15(1):99–105. doi: 10.1093/clinids/15.1.99. [DOI] [PubMed] [Google Scholar]
  10. Nelson C. T., Mason E. O., Jr, Kaplan S. L. Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment. Pediatr Infect Dis J. 1994 Jul;13(7):585–589. doi: 10.1097/00006454-199407000-00001. [DOI] [PubMed] [Google Scholar]
  11. Pankuch G. A., Jacobs M. R., Appelbaum P. C. Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother. 1995 Jan;35(1):230–232. doi: 10.1093/jac/35.1.230. [DOI] [PubMed] [Google Scholar]
  12. Pankuch G. A., Jacobs M. R., Appelbaum P. C. Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother. 1995 Jun;35(6):883–888. doi: 10.1093/jac/35.6.883. [DOI] [PubMed] [Google Scholar]
  13. Pankuch G. A., Jacobs M. R., Appelbaum P. C. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother. 1994 Sep;38(9):2065–2072. doi: 10.1128/aac.38.9.2065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Spangler S. K., Jacobs M. R., Appelbaum P. C. In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. Antimicrob Agents Chemother. 1994 Dec;38(12):2902–2904. doi: 10.1128/aac.38.12.2902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Spangler S. K., Jacobs M. R., Pankuch G. A., Appelbaum P. C. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. J Antimicrob Chemother. 1993 Feb;31(2):273–280. doi: 10.1093/jac/31.2.273. [DOI] [PubMed] [Google Scholar]
  16. Tweardy D. J., Jacobs M. R., Speck W. T. Susceptibility of penicillin-resistant pneumococci to eighteen antimicrobials: implications for treatment of meningitis. J Antimicrob Chemother. 1983 Aug;12(2):133–139. doi: 10.1093/jac/12.2.133. [DOI] [PubMed] [Google Scholar]
  17. Visalli M. A., Jacobs M. R., Appelbaum P. C. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother. 1996 Feb;40(2):362–366. doi: 10.1128/aac.40.2.362. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES